Everything set for IPO of Polish biotech OncoArendi

OncoArendi Therapeutics S.A. is ready for listing (SEC Warsaw) and, after that, it is likely to reach a PLN451.1m ($131.5m) capitalization, being its price PLN33 ($9.6) per share. Its main shareholder is currently Polish investor Michal Solowow, who owns 35.4% of the shares, followed by CEO Marcin Szumowski, with 10.2% of the shares. OncoArendi Therapeutics is a Polish biotech company focusing on the development of cancer therapies.

(Source: Parkiet)